India, Jan. 5 -- The European Medicines Agency (EMA) has informed Wockhardt that WCK 5222 (combination of Zidebactam 1g + Cefepime 2g) is eligible for Accelerated Assessment, following a pre-submission meeting with the EMA review team.The Accelerated Assessment designation reflects EMA''s view that WCK 5222 has the potential to address an unmet medical need by providing an effective therapeutic option for the treatment of following serious and life-threatening infections, particularly those caused by multi-drug-resistant (MDR) and extremely drug resistant (XDR) Gram negative pathogens.Complicated urinary tract infections (cUTI), including pyelonephritis Hospital-acquired pneumonia (HAP), including ventilator-associated pneumonia (VAP) Compl...